2024
Plasma NGAL, not IFN-γ, predicts early treatment response in drug-naïve Chinese Han schizophrenia patients
Sun X, Li M, Qiu Y, Su Q, Wang J, Bi F, Li J. Plasma NGAL, not IFN-γ, predicts early treatment response in drug-naïve Chinese Han schizophrenia patients. Schizophrenia Research 2024, 274: 457-463. PMID: 39515255, DOI: 10.1016/j.schres.2024.10.025.Peer-Reviewed Original ResearchDrug-naive schizophrenia patientsSchizophrenia patientsNeutrophil gelatinase-associated lipocalinNeutrophil gelatinase-associated lipocalin concentrationsEarly treatment responseDuration of untreated illnessTreatment responseIFN-gHealthy controlsNGAL concentrationsEarly prediction of treatment efficacyPlasma neutrophil gelatinase-associated lipocalinNeutrophil gelatinase-associated lipocalin levelsUntreated illnessPrediction of treatment efficacyPredicting early treatment responsePlasma NGAL concentrationsWeeks of treatmentIFN-g levelsPersonalized treatment strategiesLogistic regression analysisBaseline NGAL concentrationLongitudinal studySchizophreniaTreatment outcomesTargeted metabolomics-based understanding of the sleep disturbances in drug-naïve patients with schizophrenia
Yan H, Li G, Zhang X, Zhang C, Li M, Qiu Y, Sun W, Dong Y, Li S, Li J. Targeted metabolomics-based understanding of the sleep disturbances in drug-naïve patients with schizophrenia. BMC Psychiatry 2024, 24: 355. PMID: 38741058, PMCID: PMC11089724, DOI: 10.1186/s12888-024-05805-0.Peer-Reviewed Original ResearchConceptsPositive and Negative Symptom ScaleDrug-naive patientsLiquid chromatography-mass spectrometryDrug-naive schizophreniaAssociated with sleep disturbancesOrthogonal partial least squares discriminant analysisSleep disturbancePittsburgh Sleep Quality IndexPartial least-squares discriminant analysisMetabolomics-based approachNegative Symptom ScaleChromatography-mass spectrometryCharacteristic metabolitesSchizophreniaSymptom ScaleMethodsPlasma samplesPotential biological mechanismsSleep Quality IndexClinical symptomsGlycerophospholipid metabolismPartial correlation analysisHealthy controlsMetabolomic analysisPatientsBackgroundSleep disturbanceThe relationship between serum prolactin levels and cognitive function in drug-naïve schizophrenia patients: a cross-sectional study
Luo G, Bai F, Qu X, Jing Y, Wang S, Xuekelaiti Z, Yao C, Li M, Li J. The relationship between serum prolactin levels and cognitive function in drug-naïve schizophrenia patients: a cross-sectional study. Journal Of Neural Transmission 2024, 131: 385-391. PMID: 38277043, DOI: 10.1007/s00702-024-02748-4.Peer-Reviewed Original ResearchSerum prolactin levelsSchizophrenia patientsCognitive functionProlactin levelsCognitive deficitsHealthy controlsPatients serum prolactin levelsConsensus Cognitive BatterySignificant cognitive deficitsSevere cognitive deficitsCognitive batteryTreatment researchPsychiatric symptomsSchizophreniaCognitionMCCBDeficitsCross-sectional studyProlactinClinical symptomsClinical dataClinical severitySymptomsPatientsSymptomatology
2023
Altered dynamic functional connectivity of the thalamus subregions in patients with schizophrenia
Yang W, Niu H, Jin Y, Cui J, Li M, Qiu Y, Lu D, Li G, Li J. Altered dynamic functional connectivity of the thalamus subregions in patients with schizophrenia. Journal Of Psychiatric Research 2023, 167: 86-92. PMID: 37862908, DOI: 10.1016/j.jpsychires.2023.09.021.Peer-Reviewed Original ResearchDynamic functional connectivityThalamus subregionsFunctional connectivityIncreased DFCPathophysiology of schizophreniaRight fusiform gyrusHealthy controlsThalamo-cortical circuitsFusiform gyrusSZ patientsNeuroimaging studiesSchizophreniaFrontal lobeThalamusVisual-related cortexCortexSubregionsBrainnetome atlasAssociated with ageClinical featuresDysconnectivityPatientsGyrusNeuroimagingSub-regionsAssociations between metabolic disorders and sleep disturbance in patients with schizophrenia
Yan H, Huang Z, Lu Y, Qiu Y, Li M, Li J. Associations between metabolic disorders and sleep disturbance in patients with schizophrenia. Comprehensive Psychiatry 2023, 122: 152369. PMID: 36702060, DOI: 10.1016/j.comppsych.2023.152369.Peer-Reviewed Original ResearchConceptsPositive and Negative Symptom ScaleSubjective sleep qualitySleep disturbanceSleep latencyPittsburgh Sleep Quality IndexSleep qualityNegative Symptom ScaleDuration of illnessLonger sleep latencySchizophrenia patientsDrug-naiveRate of MDSchizophreniaAssociated with MDSymptom ScaleMental illnessSleep Quality IndexTotal scorePartial correlation analysisImprove sleep qualityMetabolic disordersDevelopment of MDPredictors of MDBody mass indexClinical correlates
2021
The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial
Li M, Liu Y, Qiu Y, Zhang J, Zhang Y, Zhao Y, Jia Q, Li J. The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial. Psychiatry Research 2021, 300: 113899. PMID: 33812218, DOI: 10.1016/j.psychres.2021.113899.Peer-Reviewed Original ResearchConceptsAdjunctive treatmentNon-psychiatric patientsDouble-blindSerum prolactin concentrationsPlacebo-controlled clinical trialSchizophreniaMetabolic disturbancesGlycolipid metabolic parametersBaseline body mass indexImprove metabolic disturbancesLow-density lipoprotein cholesterolProlactin concentrationsSixty-five patientsFasting serum insulinWeek 8Body mass indexEffects of berberineLipoprotein cholesterolMass indexPlaceboWeek 4Previous studiesClinical trialsMetabolic parametersTotal cholesterol